MedTrace Logo

Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients

NCT02612948 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2015-11-24

No results posted yet for this study

Summary

Scheduled, low-dose quetiapine is effective in preventing delirium in high-risk critically ill, trauma/surgical patients. Prophylaxis also reduced ventilator duration and ICU length of stay.

Conditions

  • Psychomotor Agitation

Interventions

DRUG

Quetiapine

escalating dose to prevent delerium.

Sponsors & Collaborators

  • University of Tennessee Graduate School of Medicine

    lead OTHER

Principal Investigators

  • Brian Daley · University General Surgeons, P.C.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02612948 on ClinicalTrials.gov